No abstract available.
Islets of Langerhans* ; Pancreas*

No abstract available.
Animals ; Genotype* ; Heart-Lung Transplantation* ; Humans ; Mice* ; Tissue Donors*

No abstract available.
Delirium* ; Sweat* ; Sweating*

No abstract available.
Tetanus*

No abstract available.
Allografts* ; Anemia, Hemolytic* ; Cadaver* ; Transplantation*

No abstract available.
Leiomyosarcoma ; Vena Cava, Inferior

Over the 1 year 3 month period from 7/11/1997 until 10/30/1998, we have attempted graft salvage with tacrolimus conversion in a total of 11 patients (mean age 41 years, range 31~64 years) with ongoing rejection on baseline CsA immunosuppression after failure of high dose corticosteroid to reverse rejection. The indications for conversion to tacrolimus were ongoing biosy confirmed rejection in all patients. Seven grafts showed vascular rejection and 4 had cellular rejection on biopsy. The median interval to tacrolimus conversion was 4 days (range 1 days to 840 days) after transplantation. Three patients (27.3%) were dialysis-dependent owing to the severity of rejection. All patients (100%) have been successfully rescued and graft function of the patients improved from an average serum creatinine level of 7.3 3.6 mg/dl to 1.4 0.5 mg/dl. During the mean follow-up of 8.1 months after conversion, there were 10 complications following tacrolimus conversion including cytomegalovirus (CMV) infection in 2 patient, herpes esophagitis in 1, aspergillosis pneumonia in 1, pneumocystis carinii pneumonia in 1, new-onset diabetes mellitus in 4, tremor in 1 and bleeding due to thrombocytopenic thrombocytopenic purpura (TTP) in 1. Two of these postconversion complications resulted in patient death. Treatment with tacrolimus may successfully suppress ongoing acute rejection, even if high dose corticosteoid treatment have failed to reverse rejection. Base on these data, we recommend that tacrolimus be used for refractory rejection therapy. An additional anti-infective prophylaxis seems to be necessary in preventing severe complications after rejection therapy.
Allografts* ; Aspergillosis ; Biopsy ; Creatinine ; Cytomegalovirus ; Diabetes Mellitus ; Esophagitis ; Follow-Up Studies ; Hemorrhage ; Humans ; Immunosuppression ; Pneumonia ; Pneumonia, Pneumocystis ; Purpura, Thrombocytopenic ; Tacrolimus* ; Transplants ; Tremor

No abstract available.
Animals ; Mice* ; T-Lymphocytes*

Pancreas transplantation is primarily performed in type I juvenile onset diabetes mellitus(DM). At present the patients selected for transplantation often have complications such as end-stage renal disease, neuropathy and far advanced retinopathy. These days, the survival of pancreas transplantation for treatment of patients with type I DM has improved especially in simultaneous pancreas and renal transplantation. Various innovations in immunosuppression, management of the pancreatic exocrine secretion, recipient selection and HLA matching have contributed to achieving a reasonable outcome in pancreatic transplantation compared with other organ transplantations. Current improved graft survival has stimulated many centers in the world to become interested in pancreas transplantation program. We successfully performed the first case of simultaneous pancreas and kidney transplantation in our country in August 1992. Until now, 14 cases of pancreas transplantation have been performed in 3 centers, including our 12 cases.
Diabetes Mellitus, Type 1 ; Graft Survival ; Humans ; Immunosuppression ; Kidney Failure, Chronic ; Kidney Transplantation ; Organ Transplantation ; Pancreas Transplantation* ; Pancreas* ; Transplantation ; Transplants

Accelerated acute rejection(AAR) is a rare condition and has a poor prognosis in graft survival following renal transplantation. To elucidate its characteristics, we analysed 14 cases(5.0%) of AAR among 279 renal transplantation. AAR is defined as a condition in which immediate postoperative urine output is good followed by decreased urine output and increase of serum creatinine level within 7 days after transplantation. The incidence of AAR was more prevalent in cadaveric donors than living donors. One year graft survival was inferior in AAR, namely 8 out 14 cases(57%), than that of the patients without AAR(95.1%). Among the factors affecting graft survival in AAR, age and sex of both donor and recipient, donor condition such as living or cadaveric donor, and preoperative HLA matching had no relevance to a graft survival. Time of onset of AAR has no effect on graft survival either. Postoperative donor lymphocytotoxic test showed positive result in one out of 3 patient despite of all negative findings in the preoperative crossmatching test. Histologic finding such as vasculitis on renal biopsy was related to graft survival. Response of treatment was 55% in initial solumedrol pulse therapy and 20% in secondary OKT3 treatment, with an overall effect of 57%. Rerejection developed in 4 out of 8 cases of graft survival group while all cases showed a good function at post operative two years. Graft survival following AAR remains low and AAR is one of the main cause of graft loss following renal transplantation. To illustrate its characteristics, more clinical analysis are required.
Allografts* ; Biopsy ; Cadaver ; Creatinine ; Graft Survival ; Humans ; Incidence ; Kidney Transplantation ; Living Donors ; Methylprednisolone Hemisuccinate ; Muromonab-CD3 ; Prognosis ; Tissue Donors ; Transplants ; Vasculitis